# Genentech Inc.

Canonical: https://abierto.us/vendors/genentech-inc-f7f8gzxl7q93

- UEI: F7F8GZXL7Q93
- CAGE: 1HZ12
- Parent: Roche Holding AG
- Location: South San Francisco, CA
- Awards in window: 2 (14 transactions), $69,390,394 obligated, March 13, 2024 to July 29, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $68,304,864
- Food and Drug Administration: 1 awards, $1,085,530

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $69,390,394

## Competition

- Full and Open Competition: 2 awards

## Largest awards

- 75A50118D00036: $68,304,864, Barda - Aspr / Daappo / Barda DCMA. Supplemental Funding, Revise Ottr, and Revise Statement of Work.. https://www.usaspending.gov/award/CONT_IDV_75A50118D00036_7505/
- 75F40125C00069 (definitive contract): $1,085,530, FDA Office of Acq Grant SVCS. This Project Focuses on Addressing Critical Challenges in the Design and Analysis of Hybrid Randomized Controlled Trials (Rcts) in Longitudinal Settings. the First Goal Is to Develop Causal Methodologies for Managing Diverse Missing Data Patterns in. https://www.usaspending.gov/award/CONT_AWD_75F40125C00069_7524_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/genentech-inc-f7f8gzxl7q93.